PDB Short entry for 1LG3 HEADER TRANSFERASE 15-APR-02 1LG3 TITLE THEORETICAL STRUCTURE OF HUMAN-CYCLIN DEPENDENT KINASE 7 TITLE 2 (CDK7) COMPND MOL_ID: 1; COMPND 2 MOLECULE: CELL DIVISION PROTEIN KINASE 7; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: CYCLIN-DEPENDENT KINASE 7, CDK7; COMPND 5 EC: 2.7.1.- SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN KEYWDS TRANSFERASE, SERINE/THREONINE-PROTEIN KINASE, ATP-BINDING, KEYWDS 2 PHOSPHORYLATION, CELL CYCLE, CELL DIVISION, NUCLEAR PROTEIN, KEYWDS 3 TRANSCRIPTION REGULATION, DNA REPAIR EXPDTA THEORETICAL MODEL AUTHOR K.NARAYANA,R.C.HARINARAYANA,J.A.R.P.SARMA REVDAT 1 01-MAY-02 1LG3 0 JRNL AUTH K.NARAYANA,R.C.HARINARAYANA,J.A.R.P.SARMA JRNL TITL THEORETICAL STRUCTURE OF HUMAN - CYCLIN DEPENDENT JRNL TITL 2 KINASE 7 (CDK7) JRNL REF TO BE PUBLISHED JRNL REFN REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH S.AKOULITCHEV,D.REINBERG REMARK 1 TITL THE MOLECULAR MECHANISM OF MITOTIC INHIBITION OF REMARK 1 TITL 2 TFIIH IS MEDIATED BY PHOSPHORYLATION OF CDK7 REMARK 1 REF GENES DEV. V. 12 3541 1998 REMARK 1 REFN ASTM GEDEEP US ISSN 0890-9369 REMARK 1 REFERENCE 2 REMARK 1 AUTH F.TIRODE,D.BUSSO,F.COIN,J.M.EGLY REMARK 1 TITL RECONSTITUTION OF THE TRANSCRIPTION FACTOR TFIIH: REMARK 1 TITL 2 ASSIGNMENT OF FUNCTIONS FOR THE THREE ENZYMATIC REMARK 1 TITL 3 SUBUNITS, XPB, XPD, AND CDK7 REMARK 1 REF MOL.CELL V. 3 87 1999 REMARK 1 REFN ASTM MOCEFL US ISSN 1097-2765 REMARK 1 REFERENCE 3 REMARK 1 AUTH R.P.FISHER,D.O.MORGAN REMARK 1 TITL A NOVEL CYCLIN ASSOCIATES WITH MO15/CDK7 TO FORM REMARK 1 TITL 2 THE CDK-ACTIVATING KINASE REMARK 1 REF CELL (CAMBRIDGE,MASS.) V. 78 713 1994 REMARK 1 REFN ASTM CELLB5 US ISSN 0092-8674 REMARK 1 REFERENCE 4 REMARK 1 AUTH J.P.TASSAN,S.J.SCHULTZ,J.BARTEK,E.A.NIGG REMARK 1 TITL CELL CYCLE ANALYSIS OF THE ACTIVITY, SUBCELLULAR REMARK 1 TITL 2 LOCALIZATION, AND SUBUNIT COMPOSITION OF HUMAN CAK REMARK 1 TITL 3 (CDK-ACTIVATING KINASE) REMARK 1 REF J.CELL.BIOL. V. 127 467 1994 REMARK 1 REFN ISSN 0021-9525 REMARK 1 REFERENCE 5 REMARK 1 AUTH H.SONG,N.HANLON,N.R.BROWN,M.E.NOBLE,L.N.JOHNSON, REMARK 1 AUTH 2 D.BARFORD REMARK 1 TITL PHOSPHOPROTEIN-PROTEIN INTERACTIONS REVEALED BY REMARK 1 TITL 2 THE CRYSTAL STRUCTURE OF KINASE-ASSOCIATED REMARK 1 TITL 3 PHOSPHATASE IN COMPLEX WITH PHOSPHOCDK2 REMARK 1 REF MOL.CELL V. 7 615 2001 REMARK 1 REFN ASTM MOCEFL US ISSN 1097-2765 REMARK 1 REFERENCE 6 REMARK 1 AUTH C.E.ARRIS,F.T.BOYLE,A.H.CALVERT,N.J.CURTIN, REMARK 1 AUTH 2 J.A.ENDICOTT,E.F.GARMAN,A.E.GIBSON,B.T.GOLDING, REMARK 1 AUTH 3 S.GRANT,R.J.GRIFFIN,P.JEWSBURY,L.N.JOHNSON, REMARK 1 AUTH 4 A.M.LAWRIE,D.R.NEWELL,M.E.NOBLE,E.A.SAUSVILLE, REMARK 1 AUTH 5 R.SCHULTZ,W.YU REMARK 1 TITL IDENTIFICATION OF NOVEL PURINE AND PYRIMIDINE REMARK 1 TITL 2 CYCLIN-DEPENDENT KINASE INHIBITORS WITH DISTINCT REMARK 1 TITL 3 MOLECULAR INTERACTIONS AND TUMOR CELL GROWTH REMARK 1 TITL 4 INHIBITION PROFILES REMARK 1 REF J.MED.CHEM. V. 43 2797 2000 REMARK 1 REFN ASTM JMCMAR US ISSN 0022-2623 REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : NULL REMARK 3 AUTHORS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: MODELLER OF INSIGHTII,ACCELRYS WAS REMARK 3 USED FOR MODELLING. IT USES CONJUGATE GRADIENT OPTIMISATION, REMARK 3 MOLECULAR DYNAMICS AND SIMULATED ANNEALING. REMARK 4 REMARK 4 1LG3 COMPLIES WITH FORMAT V. 2.3, 09-JULY-1998 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 19-APR-2002. REMARK 100 THE RCSB ID CODE IS RCSB015918. REMARK 220 REMARK 220 EXPERIMENTAL DETAILS REMARK 220 EXPERIMENT TYPE : THEORETICAL MODELLING REMARK 220 REMARK 220 REMARK: COMPARATIVE MODELLING REMARK 225 REMARK 225 THEORETICAL MODEL REMARK 225 THE COORDINATES IN THIS ENTRY REPRESENT A MODEL STRUCTURE. REMARK 225 PROTEIN DATA BANK CONVENTIONS REQUIRE THAT CRYST1 AND REMARK 225 SCALE RECORDS BE INCLUDED, BUT THE VALUES ON THESE REMARK 225 RECORDS ARE MEANINGLESS. REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LEU A 109 158.48 100.11 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1E1V RELATED DB: PDB REMARK 900 1E1V CHAIN A HAS 64% SEQUENCE SIMILARITY (3E-72) WITH CDK7 REMARK 900 RELATED ID: 1FQ1 RELATED DB: PDB REMARK 900 1FQ1 CHAIN B HAS 64% SEQUENCE SIMILARITY (1E-71) WITH CDK7 DBREF 1LG3 A 1 307 UNP P50613 CDK7_HUMAN 1 307 SEQRES 1 A 307 MET ALA LEU ASP VAL LYS SER ARG ALA LYS ARG TYR GLU SEQRES 2 A 307 LYS LEU ASP PHE LEU GLY GLU GLY GLN PHE ALA THR VAL SEQRES 3 A 307 TYR LYS ALA ARG ASP LYS ASN THR ASN GLN ILE VAL ALA SEQRES 4 A 307 ILE LYS LYS ILE LYS LEU GLY HIS ARG SER GLU ALA LYS SEQRES 5 A 307 ASP GLY ILE ASN ARG THR ALA LEU ARG GLU ILE LYS LEU SEQRES 6 A 307 LEU GLN GLU LEU SER HIS PRO ASN ILE ILE GLY LEU LEU SEQRES 7 A 307 ASP ALA PHE GLY HIS LYS SER ASN ILE SER LEU VAL PHE SEQRES 8 A 307 ASP PHE MET GLU THR ASP LEU GLU VAL ILE ILE LYS ASP SEQRES 9 A 307 ASN SER LEU VAL LEU THR PRO SER HIS ILE LYS ALA TYR SEQRES 10 A 307 MET LEU MET THR LEU GLN GLY LEU GLU TYR LEU HIS GLN SEQRES 11 A 307 HIS TRP ILE LEU HIS ARG ASP LEU LYS PRO ASN ASN LEU SEQRES 12 A 307 LEU LEU ASP GLU ASN GLY VAL LEU LYS LEU ALA ASP PHE SEQRES 13 A 307 GLY LEU ALA LYS SER PHE GLY SER PRO ASN ARG ALA TYR SEQRES 14 A 307 THR HIS GLN VAL VAL THR ARG TRP TYR ARG ALA PRO GLU SEQRES 15 A 307 LEU LEU PHE GLY ALA ARG MET TYR GLY VAL GLY VAL ASP SEQRES 16 A 307 MET TRP ALA VAL GLY CYS ILE LEU ALA GLU LEU LEU LEU SEQRES 17 A 307 ARG VAL PRO PHE LEU PRO GLY ASP SER ASP LEU ASP GLN SEQRES 18 A 307 LEU THR ARG ILE PHE GLU THR LEU GLY THR PRO THR GLU SEQRES 19 A 307 GLU GLN TRP PRO ASP MET CYS SER LEU PRO ASP TYR VAL SEQRES 20 A 307 THR PHE LYS SER PHE PRO GLY ILE PRO LEU HIS HIS ILE SEQRES 21 A 307 PHE SER ALA ALA GLY ASP ASP LEU LEU ASP LEU ILE GLN SEQRES 22 A 307 GLY LEU PHE LEU PHE ASN PRO CYS ALA ARG ILE THR ALA SEQRES 23 A 307 THR GLN ALA LEU LYS MET LYS TYR PHE SER ASN ARG PRO SEQRES 24 A 307 GLY PRO THR PRO GLY CYS GLN LEU HELIX 1 1 ASN A 56 LEU A 69 1 14 HELIX 2 2 LEU A 98 SER A 106 1 9 HELIX 3 3 LYS A 115 HIS A 131 1 17 HELIX 4 4 LYS A 139 ASN A 141 5 3 HELIX 5 5 GLY A 157 GLY A 163 1 7 HELIX 6 6 ALA A 180 GLY A 186 1 7 HELIX 7 7 VAL A 192 ARG A 209 1 18 HELIX 8 8 SER A 217 GLY A 230 1 14 HELIX 9 9 PRO A 256 PHE A 261 1 6 HELIX 10 10 GLY A 265 PHE A 276 1 12 HELIX 11 11 THR A 285 MET A 292 1 8 HELIX 12 12 LYS A 293 SER A 296 5 4 SHEET 1 A 5 TYR A 12 GLU A 20 0 SHEET 2 A 5 THR A 25 ASP A 31 -1 O VAL A 26 N GLY A 19 SHEET 3 A 5 ILE A 37 LYS A 44 -1 O ILE A 40 N TYR A 27 SHEET 4 A 5 ASN A 86 ASP A 92 -1 O LEU A 89 N LYS A 41 SHEET 5 A 5 LEU A 77 HIS A 83 -1 N ASP A 79 O VAL A 90 SHEET 1 B 3 THR A 96 ASP A 97 0 SHEET 2 B 3 LEU A 143 LEU A 145 -1 O LEU A 145 N THR A 96 SHEET 3 B 3 LEU A 151 LEU A 153 -1 O LYS A 152 N LEU A 144 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000